Immuneering Corp Stock Forward View

IMRX Stock  USD 5.22  0.03  0.58%   
This Naive Prediction projection for Immuneering Corp is fitted to the equity's recent daily closes. Low error metrics relative to the price level indicate the model fits recent trading behavior well. Older observations carry less weight in the current projection as the price series extends. High SAE relative to the price level signals cumulative forecast drift over the evaluation period. The Naive Prediction model projects Immuneering Corp at 4.93 for the next trading day, below the most recent closing price. This forecast is one analytical input among many and should be assessed in the context of broader analysis.

Immuneering Corp Cash Forecast

Statistical forecasting of Immuneering Corp's financial indicators relies on detecting patterns in past data. Business cycle sensitivity and seasonal effects are factored into forward-looking estimates of Immuneering Corp's position. Statistical pattern recognition reveals recurring cycles in Immuneering Corp's cash generation. Forward-looking estimates are generated with quantified uncertainty ranges.
 
Cash  
 First Reported
2020-03-31
 Previous Quarter
227.56 million
 Current Value
128.65 million
 Quarterly Volatility
46.98 million
Macro event markers
 
Covid
 
Interest Hikes
A naive forecasting model for Immuneering Corp is a special case of the moving average where the smoothing period is one. The forecast for Immuneering Corp on a given trading day is simply the observed closing price of the previous period. Because it uses only a single lag, this model is limited to one-period-ahead forecasts.

Naive Prediction Price Forecast For the 11th of May 2026

Over a 90-day horizon, the Naive Prediction model forecasts Immuneering Corp at 4.93 for the next trading day, with a mean absolute deviation of 0.17 , mean absolute percentage error of 0.03 , and sum of absolute errors of 10.14 .
This represents a tight forecast with good short-term tracking of Immuneering Corp's price movement. This output is intended for short-term analytical reference.

Stock Forecast Pattern

Backtest Immuneering Corp  Immuneering Corp Price Prediction  Research Analysis  

Forecasted Value

Immuneering Corp's next-session forecast estimates practical downside and upside boundaries based on the model's historical fit. The projected band runs from roughly 1.51 on the downside to about 8.36 on the upside. The wide range indicates elevated uncertainty in short-term projections.
Market Value
5.22
4.93
Expected Value
8.36

Model Predictive Factors

The table below summarizes the Naive Prediction model's error metrics for Immuneering Corp stock. Lower MAD and MAPE values indicate tighter forecast accuracy. AIC measures relative model quality — lower values indicate less information loss and a better-fitting model. A large Bias suggests systematic over- or under-prediction.
AICAkaike Information Criteria115.0441
BiasArithmetic mean of the errors None
MADMean absolute deviation0.1663
MAPEMean absolute percentage error0.0313
SAESum of the absolute errors10.1415
The naive model produces a tight forecast range but offers no smoothing of noise or trend detection. It serves primarily as a baseline benchmark — if a more complex model cannot outperform the naive forecast, it may indicate that Immuneering Corp price movements are largely random over the selected horizon.

Other Forecasting Options for Immuneering Corp

Fibonacci retracement levels applied to Immuneering Corp Stock price swings identify potential support and resistance zones. Extreme price moves in Immuneering Corp occur more frequently than standard risk models assume. Support and resistance levels derived from Immuneering Corp's historical data identify zones where buying or selling pressure has stalled moves. A volume spike without a corresponding price move signals accumulation or distribution ahead of a directional breakout.

Immuneering Corp Related Equities

Immuneering Corp's market space within the Health Care space is illustrated by the firms listed below. Checking cash flow across this peer set helps gauge Immuneering Corp's relative financial strength. A stock that beats its peers on many metrics often deserves a closer look from value-focused investors. These links can also guide portfolio spreading choices within the sector.
 Risk & Return  Correlation

Immuneering Corp Market Strength Events

Rate of Change and Momentum readings for Immuneering Corp measure the velocity of recent price moves rather than direction alone. These indicators add context to how recent sessions in Immuneering Corp have behaved. These indicators are most informative when viewed alongside Immuneering Corp's volume profile and volatility measures. The Price Action Indicator distills each session's open-high-low-close into a single directional score for Immuneering Corp.

Immuneering Corp Risk Indicators

Standard deviation and variance for Immuneering Corp measure total price dispersion, while semi-deviation isolates only the downside moves. Higher variance relative to sector peers signals that Immuneering Corp's price path has been less predictable over the measured period. Analyzing Immuneering Corp's risk indicators helps explain how recent moves compare with its broader trading range. A narrow gap between mean deviation and standard deviation indicates that Immuneering Corp's return distribution is relatively symmetric.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.

Immuneering Corp Short Properties

Short-interest signals around Immuneering Corp reveal whether skeptical positioning is starting to pressure price predictability and market tone. This is applicable when the question is whether bearish pressure is starting to shape the market's reaction function.
Common Stock Shares Outstanding44.01 million
Cash And Short Term Investments172.83 million